Standout Papers

Determinants of Tumor Response and Survival With Erlotinib in Patients With Non—Small-Cell Lung... 2004 2026 2011 2018 873
  1. Determinants of Tumor Response and Survival With Erlotinib in Patients With Non—Small-Cell Lung Cancer (2004)
    Román Pérez-Soler, Abraham Chachoua et al. Journal of Clinical Oncology
  2. Dabrafenib plus trametinib in patients with previously treated BRAFV600E-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial (2016)
    David Planchard, Benjamin Besse et al. The Lancet Oncology

Immediate Impact

5 by Nobel laureates 4 from Science/Nature 95 standout
Sub-graph 1 of 16

Citing Papers

Targeted Therapies for Lung Cancer Patients With Oncogenic Driver Molecular Alterations
2022 Standout
Lung cancer
2021 Standout
17 intermediate papers

Works of James R. Rigas being referenced

Dabrafenib plus trametinib in patients with previously treated BRAFV600E-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial
2016 Standout
Prognostic and Predictive Value of Epidermal Growth Factor Receptor Tyrosine Kinase Domain Mutation Status and Gene Copy Number for Adjuvant Chemotherapy in Non-small Cell Lung Cancer
2010
and 10 more

Author Peers

Author Last Decade Papers Cites
James R. Rigas 3269 3342 2170 140 6.4k
Randolph S. Marks 2756 2647 1428 120 5.8k
Hideo Kunitoh 3383 3410 1970 217 6.4k
Guenther G. Steger 1433 4434 1260 155 5.8k
Shenhong Wu 1652 2882 1422 96 5.3k
Neeltje Steeghs 1837 2719 1610 238 5.1k
M. E. Scheulen 1146 2572 2258 178 5.5k
Daniel J. George 4532 2821 3224 253 7.8k
Rossana Berardi 2725 4061 1836 342 7.1k
Manuela Schmidinger 5213 2877 3810 177 8.2k
Tom R. Fitch 1255 1984 1158 96 4.5k

All Works

Loading papers...

Rankless by CCL
2026